Navigation Links
Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
Date:5/9/2013

RICHMOND, Calif., May 9, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier , Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10:00 am PT on Thursday, May 16, 2013, at the Bank of America Merrill Lynch 2013 Health Care Conference which will be held in Las Vegas.  

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

 

 

 


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
2. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
3. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
4. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
5. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
6. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
8. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
9. Sangamo BioSciences Reports First Quarter 2012 Financial Results
10. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
11. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... 2017 , ... NetDimensions appoints Bill Mastin, a learning technology veteran, as its ... in the learning technologies industry, Mastin joins NetDimensions from the New York office of ... At LEO, Mastin served as SVP of the North America offices and prior to ...
(Date:4/20/2017)... ... April 20, 2017 , ... Energetiq Technology , a ... that Chief Executive Officer (CEO) Debbie Gustafson has been appointed to the SEMI ... association connecting the electronics manufacturing supply chain. The mission of the SEMI NAAB ...
(Date:4/20/2017)... Minneapolis, MN and Bethesda, MD (PRWEB) , ... ... ... for Advancing Innovation announce the formation of a unique intellectual property (IP) sharing ... commercialization potential of their most promising inventions. A main component of this effort ...
(Date:4/20/2017)... HACKENSACK, N.J. and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell technologies ... Chief Executive Officer, will present at the Alliance for Regenerative ... Investor Day on Thursday, April 27, 2017 at 09:40 EDT ... Dr. Ralph Kern , MD, MHSc, Chief Medical Officer ...
Breaking Biology Technology:
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
Breaking Biology News(10 mins):